Argatroban Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 3.50 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Argatroban Market Analysis
The argatroban market is expected to register a CAGR of 3.5% over the forecast period, 2022-2027.
The COVID-19 pandemic caused disruptions in the supply chains and treatment protocols for pharmaceuticals around the world, which also influenced the global anticoagulant, specific to the argatroban market. It also delays the research and development of medications for illnesses other than COVID-19. But the rate of thrombosis among COVID-19 hospitalized patients was found to be comparatively high early in the COVID-19 pandemic. In January 2021, Thorax, an international journal from BMJ published that COVID-19 patients may experience mild thrombocytopenia, mildly extended prothrombin time, increased fibrinogen, and elevated D-dimer that may lead to thrombosis. Thus COVID-19 had a significant impact on the market. Furthermore, it is anticipated that the market under study will eventually reach its full potential because of vaccination campaigns and a decline in COVID-19 cases.
Argatroban is a medicine used to prevent blood clots and helps in the improvement of neurological symptoms (motor paralysis) and activities of daily life (walking, standing, maintaining a sitting position, diet) associated with acute cerebral thrombosis. It is also used in the treatment of chronic arterial occlusion (Buerger's disease and arteriosclerosis obliterans), also as prophylaxis and for the prevention of heparin-induced thrombocytopenia (HIT) type II. In October 2020, the American Society of Hematology published that prothrombotic adverse drug reaction known as heparin-induced thrombocytopenia (HIT) can be observed in 0.1% to 7% of patients using heparin products, depending on patient population and type of heparin used in the medication. Heparin is necessary during routine hemodialysis in order to prevent clotting in the extracorporeal circuit. So, the argatroban is used to prevent the HIT in the hemodialysis patients. The other driving factor of argatroban market is the increased prevalence of cerebral venous thrombosis that can be observed in patients with HIT. In March 2022, American Heart Association published that 1.6% of people with HIT develop cerebral venous thrombosis. Hence, the increase in the prevalence of cerebral venous thrombosis may increase the growth of the argatroban market.
However, the side effects and related allergies of argatroban treatment is expected to restrain growth in the argatroban market during the forecast period of the study.
Argatroban Market Trends
This section covers the major market trends shaping the Argatroban Market according to our research experts:
Heparin-Induced Thrombocytopenia (HIT) is Expected to Dominate the Market Over the Forecast Period
Heparin-induced thrombocytopenia (HIT) is immunemediated and associated with a risk of thrombosis. HIT is an adverse drug reaction caused by the emergence of antibodies that activate platelets in the presence of heparin which is commonly used in hemodialysis. In February 2022, the American Kidney Fund, reported that approximately 570,000 Americans receive dialysis, which shows a significant impact on heparin usage and its adverse drug reaction, Heparin-induced thrombocytopenia (HIT). Thus, demand for argatroban is expected to grow which will drive growth in the argatroban market over the forecast period of the study. Additionally, in December 2020, American Heart Association published that, those patients who received unfractionated heparin for therapeutic and surgical purposes get Heparin-induced thrombocytopenia (HIT) in 0.5% to 1% of cases and patients using low molecular weight heparin (LMWH) have a significantly decreased incidence (0.1% to 0.5%). Thus, demand for argatroban indirectly depends on the type of heparin used in clinical settings, which ultimately impacts the growth of the argatroban market.
The National Audit of Percutaneous Coronary Intervention (PCI) 2021 has published that there was a slight (less than 1%) reduction in total PCI procedures compared with the previous years due to the reduction in the proportion of National Health Service (NHS) centers performing the surgeries during 2019-2020. The use of argatroban in adult patients with or at risk for HIT will increase significantly once the National Health Service (NHS) centers resume their operations of PCI. Thus, demand for argatroban and its market is expected to grow in the forecast period.
North America is Expected to Dominate the Market Over the Forecast Period
North America is expected to hold a major market globally due to the development of new formulation products and the increasing prevalence of cardiovascular disorders like stroke, coronary artery disease, and Peripheral arterial disease caused mainly due to the occlusion of blood vessels with thrombosis. In 2022, the Centers for Disease Control and Prevention published that there are approximately 900,000 people affected each year in the United States with thromboembolic events. The major risks for blood clots include older age, obesity, recent surgery or injury, family history of blood clots, cancer treatment, and other lifestyle changes like smoking.
Moreover, peripheral artery disease is a chronic occlusive disease that limits blood flow of the arterial circulation to the lower extremities. Argatroban is the drug used in the treatment of chronic arterial occlusion. So, an increase in the prevalence of peripheral artery disease will have a significant impact on the usage of argatroban. In June 2021, Circulation Research published that the prevalence of peripheral artery disease (PAD) was projected to be 7% in the United States, affecting 8.5 million persons. All these factors and an increase in the prevalence of cardiovascular risk factors, along with the risk of thrombosis in the region are expected to drive the argatroban market over the forecast period.
Argatroban Industry Overview
The argatroban market is fragmented in nature due to the presence of several companies operating globally. The major players include Mitsubishi Tanabe Pharma, AuroMedics Pharma LLC, Fresenius Kabi USA, Pfizer Inc, Novartis AG, Hikma Pharmaceuticals PLC, Par Pharmaceutical, Daiichi Sankyo Company, Limited, Viatris Inc, Caplin Steriles Ltd.
Argatroban Market Leaders
-
Mitsubishi Tanabe Pharma Corporation
-
AuroMedics Pharma LLC
-
Pfizer Inc
-
Viatris Inc
-
Hikma Pharmaceuticals PLC
*Disclaimer: Major Players sorted in no particular order
Argatroban Market News
- In June 2021, Accord Healthcare received the United States Food and Drug Administration approval for Argatroban in Sodium Chloride.
- In January 2021, Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited, was granted final approval from the United States Food and Drug Administration for its abbreviated new drug application (ANDA) argatroban injection.
Argatroban Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increased Use of Argatroban in Heparin-induced Thrombocytopenia
- 4.2.2 Increase in Prevalence of Cerebral Venous Thrombosis
-
4.3 Market Restraints
- 4.3.1 Side Effects and Related Allergies of Argatroban
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Indication
- 5.1.1 Buerger's Disease
- 5.1.2 Arteriosclerosis Obliterans
- 5.1.3 Heparin-Induced Thrombocytopenia (HIT)
- 5.1.4 Percutaneous Coronary Intervention
- 5.1.5 Other Indications
-
5.2 By End User
- 5.2.1 Hospital Pharmacies
- 5.2.2 Retail Pharmacies
- 5.2.3 Other End Users
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Mitsubishi Tanabe Pharma
- 6.1.2 AuroMedics Pharma LLC
- 6.1.3 Fresenius Kabi USA
- 6.1.4 Pfizer Inc
- 6.1.5 Novartis AG
- 6.1.6 Hikma Pharmaceuticals PLC
- 6.1.7 Par Pharmaceutical
- 6.1.8 Daiichi Sankyo Company, Limited
- 6.1.9 Viatris Inc
- 6.1.10 Caplin Steriles Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityArgatroban Industry Segmentation
As per the scope of the report, argatroban is a direct thrombin inhibitor that prevents the clotting of blood. It is used in conditions such as Heparin-induced thrombocytopenia (HIT) and prevents blood coagulation during percutaneous coronary intervention. The Argatroban Market is segmented by Indication (Buerger's Disease, Arteriosclerosis Obliterans, Heparin-Induced Thrombocytopenia (HIT) Type II, Percutaneous Coronary Intervention and Other Indications), End User (Hospital Pharmacies, Retail Pharmacies, Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Indication | Buerger's Disease | |
| Arteriosclerosis Obliterans | ||
| Heparin-Induced Thrombocytopenia (HIT) | ||
| Percutaneous Coronary Intervention | ||
| Other Indications | ||
| By End User | Hospital Pharmacies | |
| Retail Pharmacies | ||
| Other End Users | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Argatroban Market Research FAQs
What is the current Global Argatroban Market size?
The Global Argatroban Market is projected to register a CAGR of 3.5% during the forecast period (2024-2029)
Who are the key players in Global Argatroban Market?
Mitsubishi Tanabe Pharma Corporation, AuroMedics Pharma LLC, Pfizer Inc, Viatris Inc and Hikma Pharmaceuticals PLC are the major companies operating in the Global Argatroban Market.
Which is the fastest growing region in Global Argatroban Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Argatroban Market?
In 2024, the North America accounts for the largest market share in Global Argatroban Market.
What years does this Global Argatroban Market cover?
The report covers the Global Argatroban Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Argatroban Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Argatroban Industry Report
Statistics for the 2024 Global Argatroban market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Argatroban analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
